Lee:Literature Proteasomes

Feel free to add articles ...

• Proteasome Biology general review

1. Alrefai WA and Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res. 2007 Oct;24(10):1803-23. DOI:10.1007/s11095-007-9289-1 |
2. Dawson PA, Lan T, and Rao A. Bile acid transporters. J Lipid Res. 2009 Dec;50(12):2340-57. DOI:10.1194/jlr.R900012-JLR200 |
3. DuBuske LM. The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions. Drug Saf. 2005;28(9):789-801. DOI:10.2165/00002018-200528090-00004 |

• Immunoproteasome

1. pmid=

2. pmid=

3. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, and Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum. 2007 Mar;50(3):337-48; discussion 348-50. DOI:10.1007/s10350-006-0796-7 |
4. Gavilán MP, Castaño A, Torres M, Portavella M, Caballero C, Jiménez S, García-Martínez A, Parrado J, Vitorica J, and Ruano D. Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. J Neurochem. 2009 Jan;108(1):260-72. DOI:10.1111/j.1471-4159.2008.05762.x |
5. Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, and Orlowski RZ. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood. 2009 May 7;113(19):4667-76. DOI:10.1182/blood-2008-07-171637 |
6. Ho YK, Bargagna-Mohan P, Wehenkel M, Mohan R, and Kim KB. LMP2-specific inhibitors: chemical genetic tools for proteasome biology. Chem Biol. 2007 Apr;14(4):419-30. DOI:10.1016/j.chembiol.2007.03.008 |
7. Heink S, Fricke B, Ludwig D, Kloetzel PM, and Krüger E. Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res. 2006 Jan 15;66(2):649-52. DOI:10.1158/0008-5472.CAN-05-2872 |

8. pmid=

9. pmid=

10. pmid=

11. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C, Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi S, Pession A, Ohm T, Grune T, and Franceschi C. Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiol Aging. 2006 Jan;27(1):54-66. DOI:10.1016/j.neurobiolaging.2004.12.004 |
12. Mishto M, Luciani F, Holzhütter HG, Bellavista E, Santoro A, Textoris-Taube K, Franceschi C, Kloetzel PM, and Zaikin A. Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. J Mol Biol. 2008 Apr 11;377(5):1607-17. DOI:10.1016/j.jmb.2008.01.086 |
13. Mishto M, Bonafè M, Salvioli S, Olivieri F, and Franceschi C. Age dependent impact of LMP polymorphisms on TNFalpha-induced apoptosis in human peripheral blood mononuclear cells. Exp Gerontol. 2002 Jan-Mar;37(2-3):301-8. DOI:10.1016/s0531-5565(01)00196-6 |